glp-1 agonists how do they work Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review Science Behind GLP 1 GIP

Shocking Truth: Compounded GLP-1s on Groupon pose serious health risks

Amgens MariTide leads the GLP-1 obesity therapy market in 2025 with innovative design, Phase-3 trials, and strong potential for effective weight loss.

GLP-1 drugs could rapidly evolve beyond current use as diabetes and weight loss medications, with new research pointing to potential benefits in cancer, ageing, addiction, osteoarthritis and heart health

GLP-1 Drugs GLP-1 Drugs GLP-1 Drugs Distribution GLP-1 Drugs Distribution Dublin, March 18, 2025 (GLOBE NEWSWIRE) -- The "GLP-1 Market Industry Trends and Global Forecasts to 2035, by Type of Molecule, Active Compound Used, Type of GLP-1 Agonist Drugs, Type of Agonist, Route of Administration, Target indication and Key Geographical Regions" report has been added to ResearchAndMarkets.com's offering

This review examines the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on different heart failure phenotypes with preserved ejection fraction

63.6% female) and 18537 used an SGLT-2 inhibitor (59.8 years